glp 1 and pancreas Glucagon-like Peptide Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes GLP-1 Agonists and Pancreatitis Risk

209 Pharmacokinetic DDIs Caused by Mechanisms of Actions Following GLP-1 RAs or a Dual GLP-1/GIP RA Treatment GLP-1 RAs are currently attracting significant attention because of their remarkable weight loss-promoting effects

The SUSTAIN-6 cardiovascular outcomes trial identified a statistically significant increase in diabetic retinopathy complications among semaglutide-treated patients, particularly those with pre-existing retinopathy and rapid glucose reduction

Suppressing glucagon secretion (a hormone that raises blood glucose levels)

These findings are unusual in a patient in her 40s, but could be due to hypovolemia from semaglutide

Not that I didn't think it could work